ID | 523 |
No | 523 |
Brand Name | HALAVEN SOLUTION FOR INJECTION |
Ingredients | EACH VIAL (2 ML) CONTAINS: ERIBULIN MESYLATE 1 MG EQ.TO ERIBULIN 0.88 MG. |
Dosage Form | SOLUTION FOR INJECTION |
Primary Packaging | VIAL |
Storage | STORE BELOW 30'C |
Shelf Life | 2 YEARS |
Pack Size | BOX OF 1 VIAL X 2ML |
Dispensing Category | Prescription only |
ATC Classification | L01XX41 |
Pharmaceutical Class | ANTINEOPLASTICS |
Indications | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE PROGRESSED AFTER AT LEAST TWO CHEMOTHERAPEUTIC REGIMENS FOR ADVANCED DISEASE. PRIOR THERAPY SHOULD HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE UNLESS PATIENTS WERE NOT SUITAB |
Contraindications | - HYPERSENSITIVITY TO THE ACTIVE SUBSTANCE OR TO ANY OF THE EXCIPIENTS
- BREAST FEEDING |
Side Effects | THE MOST COMMONLY REPORTED ADVERSE REACTIONS TO ERIBULIN ARE SHOWN IN THE TABLE BELOW. |
Unit Price | - |
EDL |
No |
Description | 5 ML CLEAR GLASS VIAL CONTAINING A CLEAR, COLOURLESS SOLUTION ESPECIALLY FREE FROM VISIBLE PARTICLES OF FOREIGN MATTER |
Note | |
License Owner | DKSH LAOS COMPANY LIMITED |
Manufacturer | BSP PHARMACEUTICALS S.P.A |
Country | ITALY |
Import Registration No | EU/1/11/678/001 |
Import Registration Date | 2011-03-17 |
Activity | CERTIFICATE RELEASED |
Applied Date | 2023-08-21 |
FDD Registration No | 09 I 3897/13 |
FDD Registration Date | 2024-01-08 |
Expiry Date | 2027-01-07 |